Drug
Fingolimod
Fingolimod: highest development phase Post-Market, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fingolimod NCT04480853 | Post-Market | Multiple Sclerosis |
Latest
No recent events.
Follow Fingolimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.